Protease Inhibitors (PIs)

When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA. The CD4 cell is then "programmed" to make new HIV genetic material and HIV proteins. The proteins must be cut up by the HIV protease—a protein-cutting enzyme—to make functional new HIV particles. PIs block the protease enzyme and prevent the cell from producing new viruses. It is recommended that they be used in combination with at least two other HIV drugs to treat HIV infection.

*generic or biosimilar available

E experimental

DRUG Aptivus
GENERIC NAME tipranavir
COMPANY Boehringer Ingelheim
DRUG Crixivan
GENERIC NAME indinavir
COMPANY Merck & Company
DRUG Evotaz
GENERIC NAME atazanavir + cobicistat
COMPANY Bristol-Myers Squibb
DRUG Invirase
GENERIC NAME saquinavir
COMPANY Genentech, a division of Roche
DRUG Kaletra
GENERIC NAME lopinavir + ritonovir
DRUG Lexiva
GENERIC NAME fosamprenavir
COMPANY ViiV Healthcare
DRUG Norvir
GENERIC NAME ritonavir
DRUG Prezcobix
GENERIC NAME darunavir + cobicistat
COMPANY Janssen Therapeutics
DRUG Prezista
GENERIC NAME darunavir
COMPANY Janssen Therapeutics
DRUG Reyataz*
GENERIC NAME atazanavir
COMPANY Bristol-Myers Squibb
DRUG Viracept
GENERIC NAME nelfinavir
COMPANY ViiV Healthcare

Last Reviewed: March 14, 2019


Hot topics